[Interview with Prof. Dr. H. J. Rupprecht about secondary prevention: what is the optimal thrombocyte function inhibition?].
Rupprecht
H J
HJ
II. Medizinische Klinik u. Poliklinik, Johannes Gutenberg-Universität, Mainz.
D000789:Angina, Unstable / Q000097:blood / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D006801:Humans; D008134:Long-Term Care; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D055502:Secondary Prevention; D013577:Syndrome; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin